Kornimate/medical-research-clean huggingface dataset:
therapeutic effect of ethanol-gelfoam mixture for the treatment of arterioportal shunts (aps) in patients with hcc

Conditions: Carcinoma, Hepatocellular

Summary: transcatheter arterial chemoembolization (tace) is a key palliative treatment for patients with inoperable hepatocellular carcinoma (hcc). arterioportal shunts (aps) can aggravate portal hypertension and the shunts let lipiodol flow to normal liver tissue and result in poor lipiodol deposition in the tumor, causing liver ischemia. occlusion of aps is a vital and initial step for the following embolization of tumor. ethanol-gelfoam mixture(egm) and gelfoam only both can occlude aps in patients with hepatocellular carcinoma (hcc). the aim of this study was to evaluate the efficacy and safety of egm in treatment of aps in the procedure of tace, and to analyze the prognostic factors for survival in this kind of patients.


Eligibility criteria:
inclusion criteria: * age \> 18 * child-pugh a or b cirrhosis * ecog performance status grade 2 or below * no serious concurrent medical illness * no prior treatment (including surgery) for hcc * histologically or cytologically proven hcc (an alphafetoprotein level \> 500 ug/ml in the presence of radiological findings suggestive of hcc in a patient with chronic hbv or hcv infection can be considered eligible at investigator's discretion) * unresectable and locally advanced disease without extra-hepatic disease * massive expansive or nodular tumor morphology with measurable lesion on ct * size of largest tumor \<= 15cm in largest dimension * number of main tumor \<= 5, excluding associated small satellite lesions * arterioportal shunts (aps) is found in the angiography of hcc blood supply exclusion criteria: * history of prior malignancy except skin cancer * history of significant concurrent medical illness such as ischemic heart disease or heart failure * history of acute tumor rupture * serum creatinine level \> 180 umol/l * presence of biliary obstruction not amenable to percutaneous drainage * child-pugh c cirrhosis * history of hepatic encephalopathy, or * intractable ascites not controllable by medical therapy, or * history of variceal bleeding within last 3 months, or * serum total bilirubin level \> 50 umol/l, or * serum albumin level \< 28g/l, or * inr \> 1.3 * presence of extrahepatic metastasis * predominantly infiltrative lesion * diffuse tumor morphology with extensive lesions involving both lobes. * hepatic artery thrombosis, or * partial or complete thrombosis of the main portal vein, or * tumor invasion of portal branch of contralateral lobe, or * hepatic vein tumor thrombus

Keywords: hepatocellular carcinoma arterioportal shunts transarterial chemoembolization ethanol gelfoam polyvinyl alcohol foam embolization particles (pva)
compare the effect of exercise program plus dry needling versus elastic taping

Conditions: Low Back Pain

Summary: low back pain is a common musculoskeletal health condition in society. it is a leading cause of disability globally and has created a significant burden in terms of work disability and high healthcare costs. studies on the treatment of combined therapies for non-specific low back pain are scarce, so it is not known in depth which intervention is the best for reducing pain. for this reason, the objective of this study was to evaluate and compare the effect of physical exercise plus dry needling versus physical exercise plus elastic bandage. for this, a randomized clinical trial was carried out with a total of 22 people, where pain was evaluated using the ena scale and functionality using the oswestry test. participants received core stabilization exercises. core stability training has become a popular training trend and has begun to be applied in rehabilitation programs and sports medicine (1). the expected results of the study are that the group that receives the physical exercise intervention plus dry needling will have better results in reducing the pain and functionality variable, evaluated with ena and oswestry in 4 sessions.


Eligibility criteria:
inclusion criteria: * workers of the university of the americas, santiago centro campus, echaurren and república headquarters exclusion criteria: not having a diagnosis of cancer, * hernia of the nucleus pulposus with neural symptoms, * pregnant * history of recent surgery (\<6 months) * history of tumor * history of spinal fracture * people with belonephobia
role of pioglitazone in preventing diabetes

Conditions: Diabetes

Summary: a three year prospective, double blinded, placebo controlled, randomized clinical trial in impaired glucose tolerance (igt) subjects to study the effect of pioglitazone in preventing the conversion to diabetes.

a randomized controlled study was designed to find out whether pioglitazone will prevent the conversion to diabetes in subjects who are non obese and with impaired glucose tolerance. it is a double blind prospective study for 3 years. the study was started in october 2003 and randomization was completed in may 2005. a total of 6643 subjects were screened and 406 were randomized either to pioglitazone or placebo(investigator blinded-groups assigned a and b). at randomisation subjects were given standard advice on diet,exercise and benefits of life style modifications. subjects both male and female, aged between 35 and 55 years, with no known history of diabetes, willing and available for a 3 year study alone were screened. pregnant women, subjects with major illness such as cancer, hepatic or cardiac diseases and on transferable jobs were excluded from the study. the initial dose of tablet was 15mg o.d. which was titrated after a month to 30 mg o.d. in subjects who did not show any adverse events. the subjects will be undergoing annual reviews with a repeat ogtt, for 3 years. an interim review at every six months is also being done. proforma containing details of anthropometry, occupation, physical activity, dietary habits, details of medications, regularity of treatment will be done at each interview. the main expected outcomes of the study will be a reduction in conversion of igt to diabetes and benefits of the drug on anthropometric variables and biochemical parameters.

Eligibility criteria:
inclusion criteria: * both male and female * age 35 - 55 years * no known history of diabetes * willing and available for a 3 years study exclusion criteria: * pregnant women * subjects with major illness such as cancer, hepatic or cardiac diseases * transferable jobs

Keywords: impaired glucose tolerance intervention prevention
a mobile intervention to improve uptake of prep for southern black msm

Conditions: Hiv

Summary: this study will develop and test an interactive mobile messaging intervention to improve engagement in care related to pre-exposure prophylaxis (prep) and decrease hiv risk behaviors for black men who have sex with men living in the southern u.s. the mobile messaging intervention will include interactive text messaging and free, publicly available links to websites and youtube videos. during the intervention participants will gain information about their health, improve motivation for engagement in prep related care, and build skills for healthy behaviors. participants will also receive intervention materials to help decrease frequent barriers to care. if the intervention is found to be effective, it can be tested in a larger study and then disseminated.

the uptake of pre-exposure prophylaxis (prep) has been slow for young black men who have sex with men (bmsm) living in the southern united states. this is a significant issue because eight of the ten states with the highest rates of new hiv infections are located in the south. jackson, mississippi (ms) (the site of this project) has the second highest aids diagnosis rate in the nation, and the highest rate of hiv infection for young urban black men who have sex with men. this study will develop and test an engaging, interactive, and cost effective mobile messaging intervention to improve linkage to prep care for bmsm (18-35 yrs) living in jackson, ms. bmsm eligible for prep, receiving care at the university of mississippi medical center sexually-transmitted infections (sti)/hiv testing clinics, will be texted interactive links to publicly available, online content about prep and hiv prevention. links will be sent to prep eligible bmsm by 8-16 interactive text messages over 4 weeks. the material used in the intervention will be consistent with the information motivation behavior (imb) model and will address cultural and structural barriers to initiating prep care. a small randomized controlled study among 66 new participants in the clinics will examine the preliminary efficacy of the intervention compared to enhanced standard of care on attendance at a prep services appointment (the first step in initiating prep care). it is hypothesized that, compared to bmsm receiving enhanced standard of care, bmsm receiving the prep mobile messaging intervention will show greater attendance at a prep services appointment and decreased hiv risk behavior at 4 and 16 weeks.

Eligibility criteria:
inclusion criteria: * english speaking * black msm * eligible for prep * visit sti/hiv testing clinics at university of mississippi medical center * able to give consent/assent and not impaired by cognitive or medical limitations as per clinical assessment exclusion criteria: - involved in another prep or hiv prevention related study

Keywords: prep uptake msm black
preoperative injection of bevacizumab prior to vitreoretinal surgery in diabetic tractional retinal detachment

Conditions: Intravitreal Bevacizumab Injection; Pars Plana Vitrectomy; Tractional Retinal Detachment; Diabetic Retinopathy

Summary: vitreoretinal surgery for epiretinal proliferation tractional retinal detachment associated with proliferative diabetic retinopathy (pdr) is often complicated by hemorrhage from fibrovascular tissue. to control the bleeding during tissue dissection multiple measures and techniques are used. bevacizumab is an anti vegf antibody which has been used to induce regression of ocular neovascularization. its intraocular injection has been increasingly used for treatment of choroidal neovascularization (cnv) associated with age related macular degeneration (amd) with fairly good success.also it has been shown to be effective for treatment of pdr complicated with vitreous hemorrhage and iris neovascularization. we hypothesized that if anti-angiogenic agents, such as bevacizumab are injected into the vitreous cavity before vitrectomy in cases of pdr; there may be partial regression of neovascularization resulting in less intraoperative (and postoperative) hemorrhage. this can make the operation easier and shorter and lessen the need for intraocular cautery.. in this study diabetic patients who are candidated for vitrectomy with similar complexity scores will be randomized to preoperative injection or no injection of 2.5 mg bevacizumab .in the injection group, 2.5 mg of bevacizumab (0.1 ml of commercially available avastin vial, genentech, inc. south san francisco, ca) will be injected into the vitreous 3-5 days before operation. during each operation, the number of endodiathermy applications, backflush needle applications and the duration of surgery will be recorded by an independent observer. also, type of tamponade, post operation vitreous hemorrhage and 3 months postoperative visual acuities wil be recorded. all these parameters will be compared in two groups.

eligibility criteria: diabetic tractional retinal detachment-complexity score between 4 and 8 main outcome measures: best corrected visual acuity-anatomic condition of the retine(re-attachment of the retina)

Eligibility criteria:
inclusion criteria: * those patients with tractional retinal detachment who are candidated for pars plana vitrectomy. * complexity score between 4 and 8. exclusion criteria: * previous vitreoretinal surgery. * presence of any other vitreoretinal pathology such as past or present uveitis, and retinal artery or vein occlusion.

Keywords: intravitreal bevacizumab injection pars plana vitrectomy tractional retinal detachment diabetic retinopathy
the effects of increased inoculum on oral rotavirus vaccine take and immunogenicity

Conditions: Rotavirus Infection; Vaccine Response Impaired; Vaccine Virus Shedding

Summary: rotavirus is the leading cause of diarrhea in children worldwide. oral rotavirus vaccines work remarkably well in high-income countries, but for unclear reasons they underperform in low-income countries. a double-blind, randomized control trial will be performed to evaluate whether using a higher dose of a currently licensed vaccine (rotarix, glaxosmithkline) can improve immune responses among infants in dhaka, bangladesh. infants will be randomized 1:1 to receive either a standard or a double dose of rotarix at 6 and 10 weeks of life. infants will be assessed for fecal vaccine shedding and serum rotavirus-specific iga responses to determine vaccine immunogenicity.


Eligibility criteria:
inclusion criteria: 1. generally healthy infant (as determined by medical officers) 2. age 0-7 days at enrolment 3. mother willing and able to provide signed informed consent 4. mother willing to allow infant to be vaccinated according to study schedule 5. mother willing to allow biological specimens, including blood, stool, and saliva, to be collected from infant according to study protocol 6. mother willing and able to adhere to study schedule exclusion criteria: 1. obvious congenital malformation 2. birth weight (if known) or enrolment weight (if birth weight unknown) \< 2000 gm 3. known immunocompromising condition in infant 4. enrolment in other vaccine research trials 5. other household member enrolled in this study

Keywords: rotavirus oral vaccines vaccine underperformance vaccine shedding
fnirs studies of music intervention of parkinson's disease

Conditions: Parkinson Disease

Summary: functional near-infrared spectroscopy (fnirs) will be used to monitor neuronal activities and connectivity to elucidate the correlation between physiological changes within the brain and the benefits of music therapy for patients afflicted with parkinson's disease (pd). this study will report on the changes in neural activities as a result of music intervention in pd.

music therapy improves neuronal activity and connectivity of healthy persons and patients with clinical symptoms of neurological diseases like parkinson's disease. despite the plethora of publications that have reported the positive effects of music interventions, little is known about how music improves neuronal activity and connectivity in afflicted patients. in this study, the investigators will use functional near-infrared spectroscopy (fnirs) to measure oxygenated- (hbo2), deoxygenated- hemoglobin (hbr), and total hemoglobin activation in various parts of the cortex. the fnirs measurement, in conjunction with the unified parkinson's disease rating scale (updrs), n-back task, and the montreal cognitive assessment (moca), will be performed at baseline, week 4 (during), week 8 (post), and week 12 (retention) of the study. the 8-week long intervention will include a daily 25-minute synchronous finger tapping (sft) intervention (two sets of ten-minute sessions with a five-minute break in between sets) with a pre-selected well-known rhythmical song. the total anticipated number of participants is 150 and the participants will be split into two groups: an intervention group and a control group. data collected from the two pd groups will be compared to baseline performances from healthy controls.

Eligibility criteria:
inclusion criteria: * aged 40-80 years old, both genders, and right handed; * clinical diagnosis of idiopathic pd according to the 2015 movement disorder society (mds) clinical diagnostic criteria for parkinson's disease; * rated as stage i to ii on the hoehn and yahr scale; * scores greater than 21 points on the montreal cognitive assessment (moca); * maintain a stable dosing of anti-pd or deep-brain stimulation (dbs) treatment throughout the duration of the study; * able to travel to and participate in the data collection process. exclusion criteria: * individuals who do not meet the inclusion criteria; * presence of significant hearing or visual impairments; * extensive previous musical training; * a history of any other neurological condition (i.e. alzheimer's disease, epilepsy, stroke) or psychiatric disorders (i.e. major depression, psychoses).

Keywords: parkinson disease music therapy fnirs controlled trials explicit & implicit timing motor control synchronous finger tapping
mechanisms of affective touch in chronic pain

Conditions: Fibromyalgia

Summary: this study compares how different types of touch found in massage therapies impact pain perception, and whether these effects differ in individuals with and without chronic pain. this study also examines psychological factors that may predict differences in touch perception in individuals with chronic pain. this research will improve our understanding of whether and how massage therapies can benefit pain and health, and whether this differs in people who suffer from chronic pain.


Eligibility criteria:
inclusion criteria: 1. ages 18-65 2. fluent in english 3. physician diagnosis of fibromyalgia but no other chronic pain conditions (patients) or no evidence of chronic pain (healthy volunteers) exclusion criteria: 1. sensory, motor, or anatomic differences or injuries relevant to study procedures 2. known anomalies of the central nervous system (including stroke, dementia, aneurysm, or personal history of psychosis) 3. pregnancy 4. inability to rate pain or sensations 5. major medical conditions such as kidney, liver, cardiovascular (hypertension, preexisting cardiac arrhythmia), autonomic, pulmonary, or neurological problems (e.g., seizure disorder) or a chronic systemic disease (e.g., diabetes). 6. history of blood clots or first-degree family members with clotting disorders 7. current use of opiate medication(s) 8. contraindications to mri if participating in pilot mri study 9. unable to identify a heat stimulus 50c or lower that generates a rating of a 7 on our vas scale 10. history of fainting or seizures 11. history of frostbite 12. open cut or sore on hand to be immersed in cold water bath 13. fracture of limb to be immersed 14. history of reynaud's phenomenon (hands get white, then blue on exposure to cold, then red on warming)
pentoxifylline and endometriosis

Conditions: Endometriosis-Associated Infertility

Summary: to prove efficacy of an immunomodulator called pentoxifylline in the treatment of endometriosis in infertile patients undergoing laparoscopy surgery


Eligibility criteria:
inclusion criteria: * infertile patients having early endometriosis as the only factor of their infertility exclusion criteria: * previous treatment for endometriosis or patients having pelvic disorders in addition to endometriosis

Keywords: endometriosis immunomodulation infertility laparoscopic surgery pentoxifylline
evaluation of the training program for community pharmacists for dispensing emicizumab (hemlibra®) in france

Conditions: Hemophilia A

Summary: haemophilia a (ha) is a rare constitutional haemorrhagic disease whose drug management is based on the use of chronic lifelong replacement therapy. the occurrence of an inhibitor is a dreaded complication that impacts conventional management, consisting in using factor viii (fviii)-based replacement therapy, most often for prophylaxis. although effective, these treatments can only be administered intravenously, leading to accessibility constraints and significant mental burden for patients and their relatives. before june 15, 2021 in france, the emicizumab (hemlibra®) was available only in hospital pharmacies for the prevention or reduction of bleedings. the introduction of the dual dispensing circuit in hospital or community pharmacies, left to patient's choice, is effective from this date. these changes have important organizational consequences for patients and health professionals alongside the pathway of care. therefore, the effectiveness of this new organization requires to be evaluated with a national french study, called paso doble demi. the aims of this study are twofold : i. to evaluate the direct impact of the training programs provided to the new placeholders of the dispensing circuit ; the community pharmacists, ii. to evaluate satisfaction of patients or their relatives regarding the emicizumab treatment whether they chose dispensing in the community pharmacy, or kept the dispensing at the hospital pharmacy. the methodology was based on the 4-level of the kirkpatrick's evaluation model; 1) the immediate reaction of community pharmacists following the trainings (reaction), 2) their knowledge acquisition (learning), 3) their professional practice (behavior) and 4 ) the patients' satisfaction related to their treatment whether dispensing in hospital or in community pharmacies (results). the paso doble demi i was based on the first three levels of the evaluation model.


Eligibility criteria:
inclusion criteria: * pharmacists practicing in a pharmacy in metropolitan france * working in a pharmacy chosen by the patient with haemophilia type a * and who have agreed to dispense emicizumab (hemlibra®) exclusion criteria: * other pharmacy staff (including pharmacy technician, biologist, pharmacy students) * retired pharmacists at the date of the study * pharmacists who no longer practice in a community pharmacy dispensing emicizumab (hemlibra®) * pharmacists who expressed opposition to participating in the study

Keywords: haemophilia a accessibility emicizumab (hemlibra®) training evaluation
expectations and needs of a glioblastoma caregiver

Conditions: Glioblastoma

Summary: cancers of the central nervous system have a poor prognosis. glioblastoma is most common glial tumor of the central nervous system. the presence of a tumour in the brain determines the particular and specific nature of care for these patients and their families. symptoms affect daily life and the balance of the family sphere.it's easy to imagine a difficult and disturbed family's daily routine. caregivers find themselves in great distress but can still benefit from support to lighten the domestic burden, and financial burden, thanks to the various recommendations of successive cancer plans. in fact, support for patients and their families during the illness and after is one of the key points of the programs in place. the aim of this research will be to provide food for thought in order to improve the support provided to family and friends.


Eligibility criteria:
inclusion criteria: * caregivers of a person with glioblastoma glioblastoma undergoing oncology treatment * caregivers aged 18 and over exclusion criteria: - patient's opposition to participating in the study

Keywords: family caregiver